



Procedures for Requesting or Viewing Proxy Information for the Combined Ordinary and Extraordinary Annual Meeting on May 7, 2014

Charenton-le-Pont, France (April 3, 2014 - 6:00 pm) – Shareholders are advised that the Combined Ordinary and Extraordinary Annual Meeting will be held on **Wednesday, May 7, 2014 at 10:30 am CEST** at Palais des Congrès de Paris, 2 place de la Porte Maillot, 75017 Paris, France.

The preliminary notice of meeting, published in the *Bulletin des Annonces Légales Obligatoires* on March 28, 2014, contains information on the agenda, the proposed resolutions and the procedures for attending and voting.

Proxy information may be viewed in the Investors section of the Essilor corporate website at <http://www.essilor.com>: “Individual Shareholder Information / Annual Shareholders’ Meetings”.

As provided for in articles R.225-88 and R.225-89 of the French Commercial Code, any shareholder may consult the proxy documents and information, as described in article R.225-83 of the French Commercial Code, at Company headquarters (147 rue de Paris, 94220 Charenton-le-Pont, France) or request that such documents be sent to him or her, by writing to Société Générale, Service des Assemblées, 32 rue du Champ de Tir, CS 30812, 44308 Nantes Cedex 03, France.

About Essilor

The world’s leading ophthalmic optics company, Essilor designs, manufactures and markets a wide range of lenses to improve and protect eyesight. Its corporate mission is to improve lives by improving sight. To support this mission, the Company allocates more than €150 million to research and innovation every year, in a commitment to continuously bring new, more effective products to market. Essilor’s flagship brands are Varilux[®], Crizal[®], Transitions[®], Definity[®], Xperio[®], Optifog[™], Foster Grant[®], Bolon[®] and Costa[®]. It also develops and markets equipment, instruments and services for eyecare professionals.

Essilor reported consolidated revenue of over €5 billion in 2013 and employs more than 55,000 people. It distributes its products in more than 100 countries with 28 plants, more than 450 prescription laboratories and edging facilities, as well as several research and development centers around the world.

For more information, please visit www.essilor.com.

The Essilor share trades on the NYSE Euronext Paris market and is included in the Euro Stoxx 50 and CAC 40 indices.

Codes and symbols: ISIN: FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP.

Investor Relations and Financial Communications

Phone: +33 (0)1 49 77 42 16